Combined use of direct antiviral drugs - paritrapevir, ritonavir, ombitasvir and dasabuvir in the treatment of patients with HCV-deterministic compensated cirrhosis in real clinical practice

Abstract

Objective: To evaluate the effi cacy and safety of a combination of direct antiviral drugs - paritrapeprivir, ritonavir, ombitasvir and dasabuvir in patients with compensated cirrhosis of HCV-etiology. Materials and methods: A prospective cohort study involved 30 patients with compensated cirrhosis of the liver with HCV etiology (class A in Child-Pugh) caused by the 1b genotype of the virus. All patients received a formal combination of direct antiviral drugs - paritrapeprivir, ritonavir, ombitasvir and dasabuvir (PROD) for 12 weeks. Effi cacy evaluation was conducted to achieve a sustained virologic response 24 weeks aft er the end of antiviral treatment (VDU 24). Results: Two weeks aft er the start of treatment the virus stopped being detected in 21 people (70%), aft er 4 weeks - in all patients. VDU 24 was also achieved in 100% of cases. One patient, operated prior to the initiation of antiviral treatment for hepatocellular carcinoma (HCC), relapsed both HCC and HCV infection 36 weeks aft er the end of the antiviral treatment. Adverse events in the form of mild headache and nausea were noted only in two patients (6.7%) and had an unexpressed and short duration. Conclusions: in real clinical practice, high effi cacy of direct antiviral drugs - PROD in patients with compensated cirrhosis of HCV-etiology (in 96.7% of patients) was demonstrated at a relatively low incidence (6.7%) of side eff ects.